title: Prostate cancer, version 1.2014.
abstract: The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.
authors: From 1Roswell Park Cancer Institute; 2Dana-Farber/Brigham and Women's Cancer Center; 3Duke Cancer Institute; 4The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; 5Huntsman Cancer Institute at the University of Utah; 6Memorial Sloan-Kettering Cancer Center; 7Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; 8Prostate Health Education Network; 9University of Washington/Seattle Cancer Care Alliance; 10Fox Chase Cancer Center; 11City of Hope Comprehensive Cancer Center; 12Massachusetts General Hospital Cancer Center; 13Robert H. Lurie Comprehensive Cancer Center of Northwestern University; 14Vanderbilt-Ingram Cancer Center; 15University of Michigan Comprehensive Cancer Center; 16Moffitt Cancer Center; 17St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; 18UCSF Helen Diller Family Comprehensive Cancer Center; 19The University of Texas MD Anderson Cancer Center; 20Patient Advocate; 21Stanford Cancer Institute; 22Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; 23The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and 24National Comprehensive Cancer Network.
authors: James L
authors: JL
authors: Mohler
authors: Philip W
authors: PW
authors: Kantoff
authors: Andrew J
authors: AJ
authors: Armstrong
authors: Robert R
authors: RR
authors: Bahnson
authors: Michael
authors: M
authors: Cohen
authors: Anthony Victor
authors: AV
authors: D'Amico
authors: James A
authors: JA
authors: Eastham
authors: Charles A
authors: CA
authors: Enke
authors: Thomas A
authors: TA
authors: Farrington
authors: Celestia S
authors: CS
authors: Higano
authors: Eric Mark
authors: EM
authors: Horwitz
authors: Mark H
authors: MH
authors: Kawachi
authors: Michael
authors: M
authors: Kuettel
authors: Richard J
authors: RJ
authors: Lee
authors: Gary R
authors: GR
authors: Macvicar
authors: Arnold W
authors: AW
authors: Malcolm
authors: David
authors: D
authors: Miller
authors: Elizabeth R
authors: ER
authors: Plimack
authors: Julio M
authors: JM
authors: Pow-Sang
authors: Sylvia
authors: S
authors: Richey
authors: Mack
authors: M
authors: Roach
authors: Eric
authors: E
authors: Rohren
authors: Stan
authors: S
authors: Rosenfeld
authors: Eric J
authors: EJ
authors: Small
authors: Sandy
authors: S
authors: Srinivas
authors: Cy
authors: C
authors: Stein
authors: Seth A
authors: SA
authors: Strope
authors: Jonathan
authors: J
authors: Tward
authors: Patrick C
authors: PC
authors: Walsh
authors: Dorothy A
authors: DA
authors: Shead
authors: Maria
authors: M
authors: Ho
mesh_terms: D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use; D012008:Recurrence
chemical_list: D011868:Radioisotopes; C581106:radium Ra 223 dichloride; D011883:Radium